COMMUNIQUÉS West-GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07/08/2024
Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS- [...]
PacBio Announces Second Quarter 2024 Financial Results
07/08/2024
MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 [...]
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
07/08/2024
TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) announces the following September 2024 investor events: Investor Conference Presentations • Morgan Stanley 22 nd Annual [...]
Elutia Announces Second Quarter 2024 Results
07/08/2024
Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a [...]
Generation Bio Reports Second Quarter 2024 Financial Results
07/08/2024
Cash balance of $217 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines [...]
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07/08/2024
Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for [...]
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/08/2024
-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On [...]
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07/08/2024
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
07/08/2024
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding [...]
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
07/08/2024
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, [...]
Keros Therapeutics Reports Second Quarter 2024 Financial Results
07/08/2024
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
electroCore Announces Second Quarter 2024 Financial Results
07/08/2024
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J., Aug. 07, [...]
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
07/08/2024
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to [...]
Assertio Reports Second Quarter 2024 Financial Results
07/08/2024
Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 [...]
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
07/08/2024
Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 [...]
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
07/08/2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed [...]
Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida
07/08/2024
ROSELAND, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a [...]
XYMOGEN XPERIENCE Dedicated Exclusively to Elevating Women’s Health
07/08/2024
A renowned lineup of experts will address wellness insights core to women’s health beyond hormones ORLANDO, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- XYMOGEN ® is excited to announce its XYMOGEN XPERIENCE Fall 2024 (XX [...]
Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned
07/08/2024
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company’s [...]

Pages